The biologics license application (BLA) seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of Neulasta Onpro, has been resubmitted to the FDA for review.
The biologics license application (BLA) seeking the approval of the on-body injector (OBI) presentation of pegfilgrastim-cbqv (Udenyca), a biosimilar of pegfilgrastim (Neulasta), has been resubmitted to the FDA for review.1
In September 2023, the regulatory agency issued a complete response letter to the BLA due to an ongoing review of inspection findings at a third-party filler.2 No issues pertaining to the safety, efficacy, trial design, labeling, drug substance manufacturing, or device design or manufacturing were noted, and no additional data or clinical trials were requested.
The resubmission follows the completion and satisfactory resolution of the agency’s review, according to a press release issued by Coherus BioSciences, Inc., the drug developer.1
“We are pleased that resolution of the FDA’s inspection findings has enabled our rapid resubmission of the Udenyca OnBody BLA supplement,” Theresa LaVallee, PhD, chief development officer at Coherus, stated in a press release. “As the CRL identified no other issues with the BLA supplement, we look forward to working closely with the agency to complete the review of the Udenyca OnBody application in a timely manner and anticipate potential approval later this year.”
According to Amgen, sales of originator Neulasta has been declining due to the market introduction of pegfilgrastim biosimilars. However, shares of Neulasta Onpro, the OBI version of Neulasta, have been steady, achieving 58% of the pegfilgrastim market share during the second quarter of 2020.
In March 2023, the FDA approved a single-dose prefilled autoinjector presentation of pegfilgrastim-cbqv to be given the day after chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia.3 The approval was based on findings included in a comprehensive analytical data package as well as a study that assessed the pharmacokinetics, pharmacodynamics, and immunogenicity of the product.
Investigators evaluated safety findings from patients who received pegfilgrastim spanning 7 randomized clinical trials (n = 932).4 In a double-blind, placebo-controlled study, patients with metastatic or nonmetastatic breast cancer who were receiving docetaxel at 100 mg/m2 every 21 days (n = 928) were randomized to pegfilgrastim at 6 mg (n = 467) or placebo (n = 461).
These patients were between the ages of 21 years and 88 years; 99% were female and 66% were Caucasian. The most frequently experienced toxicities in the pegfilgrastim arm vs the placebo arm included bone pain (31% vs 26%) and pain in the extremity (4% vs 9%). Leukocytosis was observed in less than 1% of all patients with non-myeloid malignancies who received pegfilgrastim.
Moreover, an open-label, crossover study enrolled a total of 189 patients who were randomized 1:1 to receive 1 of 2 treatment sequences of the biosimilar: pegfilgrastim-cbqv administered via the OBI device followed by prefilled syringe administration, or the reverse, with a treatment interval of 6 to 8 weeks.5 In October 2021, it was announced that the trial met all pharmacokinetic bioequivalence primary end points and a key pharmacodynamic secondary end point of absolute neutrophil count. No new safety signals were observed.
“Coherus appreciates the great collaboration with our third-party manufacturer and the swift and comprehensive actions taken to address the inspectional issues raised by the agency,” Rich Hameister, chief technical officer at Coherus, added in the press release.1 “We are all focused on bringing this excellent product to patients as quickly as possible.”
References
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.